statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb Scinai Immunotherapeutics Announces Positive...

Scinai's Psoriasis Treatment Shows Promising Results

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics has announced successful preclinical results for its new anti IL...

Scinai Immunotherapeutics Advances with Promising Q1 Results

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics Ltd. has reported its Q1 2024 financial results, showcasing a ne...

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept...

Scinai Immunotherapeutics Strives for Nasdaq Compliance

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics, a biotech company, has been granted an extension by the Nasdaq...

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity Scinai Immunotherapeutics...

Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to...

Scinai Publishes Q1 2024 Financial Results and Provides Business Update

Scinai Publishes Q1 2024 Financial Results and Provides Business Update Scinai Publishes Q1 2024 Financial Results and Provides Business Update PR Newswire JERUSALEM, July 2, 2024 JERUSALEM, July 2...

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity. Scinai Immunotherapeutics Announces...

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq...

Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.

Volume	193,567.00
52-Wk High	$14.20
52-Wk Low	$2.23

SCNI Scinai Immunotherapeutics Ltd.

About

Feed

News

Fundamentals